{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:27:45Z","timestamp":1793485665980,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["20-R142-A9780-22179"],"award-info":[{"award-number":["20-R142-A9780-22179"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010358","name":"Krista og Viggo Petersens Fond","doi-asserted-by":"publisher","award":["2021-0703"],"award-info":[{"award-number":["2021-0703"]}],"id":[{"id":"10.13039\/501100010358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009584","name":"Toyota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010306","name":"Director Kurt B\u00f8nnelycke and Wife Mrs Grethe B\u00f8nnelyckes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006426","name":"Eva og Henry Fr\u00e6nkels Mindefond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ahj.2024.02.005","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T04:26:31Z","timestamp":1707971191000},"page":"84-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-5499","authenticated-orcid":false,"given":"Camilla Fuchs","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Hempel","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massar","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Nouhravesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tuxen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Lyng","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Soeskov","family":"Davidovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thorbj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"H\u00f8jlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Antonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael Kj\u00e6r","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Eifer","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.02.005_bib0001","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ejhf.1800","article-title":"Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort","volume":"22","author":"Butt","year":"2020","journal-title":"Eur J Hear Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0003","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(99)00126-6","article-title":"Risk factors for heart failure in the elderly: a prospective community-based study","volume":"106","author":"Chen","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0004","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archinte.161.7.996","article-title":"Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study","volume":"161","author":"He","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCHEARTFAILURE.109.899070","article-title":"Chronic kidney disease and the risk of heart failure in men","volume":"4","author":"Dhingra","year":"2011","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0006","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"on behalf of the EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. Empagliflozin outcome trial in patients with chronic heart failure and a reduced ejection fraction - EMPEROR-reduced","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0010","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.02.005_bib0011","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2024.02.005_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0013","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0014","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with Type 2 diabetes mellitus and coronary artery disease","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/678159","article-title":"Obesity and inflammation: epidemiology, risk factors, and markers of inflammation","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0016","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/HJH.0b013e3283537347","article-title":"Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension","volume":"30","author":"Jordan","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2024.02.005_bib0017","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: yhe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.02.005_bib0018","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2024.02.005_bib0019","unstructured":"Alcaraz C, Fosb\u00f8l E, Joseph G, et al. NBV 2023 - Dansk Kardiologisk Selskab - Hjerteklapsygdom. 2023. https:\/\/nbv.cardio.dk\/hjerteklapsygdom (Accessed May 24 2023)"},{"key":"10.1016\/j.ahj.2024.02.005_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.02.005_bib0021","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with Type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0022","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ahj.2006.11.007","article-title":"Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale","volume":"153","author":"Whellan","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.02.005_bib0023","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1475-097X.1986.tb00790.x","article-title":"Determination of 99mTc-DTPA clearance by a single plasma sample method","volume":"6","author":"Christensen","year":"1986","journal-title":"Clin Physiol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0024","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak vo2 is related to better clinical outcomes in chronic heart failure patients","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2008.03.017","article-title":"Peak aerobic capacity predicts prognosis in patients with coronary heart disease","volume":"156","author":"Keteyian","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.02.005_bib0026","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1378\/chest.110.2.325","article-title":"The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure","volume":"110","author":"Cahalin","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2024.02.005_bib0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cardfail.2006.04.004","article-title":"Association of functional and health status measures in heart failure","volume":"12","author":"Myers","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0028","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2008.09.014","article-title":"The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study","volume":"52","author":"Bluemke","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1148\/radiol.2019182871","article-title":"Left ventricular mass at MRI and long-term risk of cardiovascular events: the multi-ethnic study of atherosclerosis (MESA)","volume":"293","author":"Kawel-Boehm","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.ahj.2024.02.005_bib0030","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0031","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0032","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ageing\/23.3.182","article-title":"Evidence for the validity of the short-form 36 questionnaire (SF-36) in an elderly population","volume":"23","author":"Lyons","year":"1994","journal-title":"Age Ageing"},{"key":"10.1016\/j.ahj.2024.02.005_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0034","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of Praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction The CAPACITY HFpEF randomized clinical trial","volume":"02111","author":"Udelson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.02.005_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.02.005_bib0036","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12020-013-0099-4","article-title":"Epicardial adipose tissue in endocrine and metabolic diseases","volume":"46","author":"Iacobellis","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ahj.2024.02.005_bib0037","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00592-017-1020-z","article-title":"Epicardial adipose tissue: at the heart of the obesity complications","volume":"54","author":"Guglielmi","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0038","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"Woerden","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0039","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0040","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.02.005_bib0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.02.005_bib0042","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12933-021-01295-6","article-title":"Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial","volume":"20","author":"Tanaka","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2024.02.005_bib0043","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/diacare.22.5.818","article-title":"Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas","volume":"22","author":"Emoto","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2024.02.005_bib0044","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing - comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2024.02.005_bib0045","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1161\/CIRCULATIONAHA.120.053463","article-title":"Metabolic effects of empagliflozin in heart failure: a randomized, double-blind, and placebo-controlled trial (Empire HF Metabolic)","volume":"143","author":"Jensen","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0046","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial","volume":"25","author":"Andersen","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0047","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/CIRCULATIONAHA.119.042287","article-title":"Aerobic exercise induces cardiac fat loss and alters cardiac muscle mass through an interleukin-6 receptor\u2013dependent mechanism","volume":"140","author":"Christensen","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.02.005_bib0048","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001285","article-title":"Left ventricular mass and the risk of sudden cardiac death: a population-based study","volume":"3","author":"Laukkanen","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.02.005_bib0049","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jmri.10262","article-title":"Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences","volume":"17","author":"Alfakih","year":"2003","journal-title":"J Magn Reson imaging"},{"key":"10.1016\/j.ahj.2024.02.005_bib0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-gallego","year":"2021","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2024.02.005_bib0051","series-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2012"},{"key":"10.1016\/j.ahj.2024.02.005_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013096","article-title":"To condition or not condition? Analysing \u2018change\u2019 in longitudinal randomised controlled trials","volume":"6","author":"Coffman","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ahj.2024.02.005_bib0053","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistic Soc, 57: 289-300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"10.1016\/j.ahj.2024.02.005_bib0054","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.02.005_bib0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","article-title":"Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial","volume":"253","author":"Harrington","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.02.005_bib0056","unstructured":"NIH. ClinicalTrials.gov: dapagliflozin effects on cardiovascular events in patients with an acute heart attack (DAPA-MI). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742 (Accessed May 24 2023)"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:59:31Z","timestamp":1762077571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":56,"alternative-id":["S0002870324000322"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.02.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}